Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial (COMING study)

At 24 weeks, HbA1c levels were significantly lower in the semaglutide group (6.7 ± 0.5%) compared to the dulaglutide group (7.4 ± 0.8%) (p < .0001).

• Semaglutide resulted in a greater reduction in body mass index and visceral fat area compared to dulaglutide (p < .05).
• The rate of achieving HbA1c <7% was higher in the semaglutide group (p < .0001).
• Significant decreases in low-density lipoprotein cholesterol and liver enzymes were observed in the semaglutide group.
• Only the semaglutide group showed an improvement in the apolipoprotein B/A1 ratio, which may indicate reduced myocardial infarction risk.
• Gastrointestinal symptoms were reported in 46.3% of the semaglutide group compared to 13.2% in the dulaglutide group (p < .01).
• Quality of life scores related to pain and gastrointestinal symptoms were better in the dulaglutide group.

AI simplified